Penwest Pharmaceutical Initiates Second Phase IIa Clinical Trial for A0001

PATTERSON, N.Y., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced that it has initiated a Phase IIa clinical trial for A0001 in patients with the A3243G mitochondrial DNA point mutation and evidence of impaired mitochondrial function. This point mutation is commonly associated with MELAS syndrome. The study is being conducted at the Newcastle upon Tyne Hospitals in Newcastle, England. Newcastle is a specialist neuroscience center in the United Kingdom that offers comprehensive services for both adults and children suspected of having a rare mitochondrial disorder.